Investing News NetworkNovember 13, 2024PRISM MarketView a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. ( NASDAQ: CRDL, TSX: CRDL ) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector.

投资新闻网2024年11月13日PRISM MarketView是一家领先的市场见解和公司新闻提供商，它骄傲地宣布Cardiol Therapeutics Inc.（纳斯达克股票代码：CRDL，多伦多证券交易所股票代码：CRDL）已被添加到PRISM Emerging Biotech Index中，该指数突出了生物技术领域领先创新和创造市场影响力的公司。

Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol专注于心脏病的抗炎和抗纤维化治疗，包括其主要候选药物CardiolRx™，使其成为解决心脏护理主要未满足需求的先驱。美国FDA已授予CardiolRx™孤儿药名称，用于治疗心包炎，包括复发性心包炎。

Cardiol's MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial.

Cardiol在复发性心包炎（一种心包炎性疾病）中的MAVERIC计划包括II期MAVERIC试点研究（NCT05494788），II/III期MAVERIC-2试验和计划的III期MAVERIC-3试验。

The MAVERIC-2 trial will evaluate the impact of CardiolRx™ in recurrent pericarditis patients following the cessation of interleukin-1 blocker therapy. MAVERIC-2 is expected to initiate in Q4 2024 at major pericardial disease centers across the United States and Europe, with results anticipated ahead of the company's planned pivotal Phase III MAVERIC-3 trial.

MAVERIC-2试验将评估停止白细胞介素-1阻滞剂治疗后CardiolRx™对复发性心包炎患者的影响。MAVERIC-2预计将于2024年第四季度在美国和欧洲的主要心包疾病中心启动，预计结果将在该公司计划的关键性III期MAVERIC-3试验之前获得。

Recurrent pericarditis affects approximately 38,000 patients in the United States annually who have experienced at least one recurrence. The global pericarditis market was valued at $2.44 billion in 2023 and is projected to grow at a CAGR of 5.24% during the forecast period of 2024-2032, reaching $3.87 billion by.

复发性心包炎每年影响美国约38000名至少复发一次的患者。2023年，全球心包炎市场价值24.4亿美元，预计2024-2032年的复合年增长率将达到5.24%，到年将达到38.7亿美元。